| アブストラクト | BACKGROUND: Little is known regarding the association between adverse events (AEs) and psychiatric medications administered to pregnant women in clinical trials during the pre-marketing period. This study analyzes reports of AE association with psychiatric medication administrated during pregnancy using post-marketing spontaneous reports of AE from the Japanese Adverse Drug Event Report (JADER) database and Food and Drug Administration Adverse Event Reporting System in the United States (FAERS-US). METHODS: We summarized AE reports of psychiatric medication administrated during pregnancy by comparing data obtained from JADER and FAERS-US databases with medication patterns determined as classes via latent class analysis. The odds ratios (ORs) of AE reports categorized into system organ classes in which each class was compared with those without psychiatric medications. RESULTS: The proportions of AE reports under psychiatric medication in pregnancy among all AE reports were 22.0% and 16.6% in JADER and FAERS-US, respectively. The 10,389 reports of psychiatric medication during pregnancy were classified into 11 classes. The proportion of patients receiving four or more psychiatric drugs in JADER was larger than that in FAERS-US. The maximum number of reports in combinations of AE and medication pattern in JADER was 169, for 'general disorders and administration site conditions' from the class of four or more medications (OR = 9.1), while that in FAERS-US was 1,654, for 'injury, poisoning, and procedural complications' from the class of single psychiatric medication (OR = 2.8). CONCLUSIONS: The main AE reports and associated AE differed depending on medication patterns in pregnant women taking psychiatric medication. This study may provide a prediction of AEs that are likely to be reported with each medication pattern. Our findings of the association between AE reports and medication patterns could help improve the administration of psychiatric medications during pregnancy, though further research on additional datasets is needed to clarify these results. |
|---|
| 組織名 | Keio University Graduate School of Health Management, 4411 Endo, Fujisawa-shi,;Kanagawa, 252-0883, Japan. tanzai04@keio.jp.;Statistics Analysis Department 1, EPS Corporation, 6-85 Shinogawa-machi,;Shinjuku-ku, Tokyo, 162-0815, Japan. tanzai04@keio.jp.;Department of Biostatistics, Nagoya University Graduate School of Medicine, 65;Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.;Kanagawa, 252-0883, Japan.;Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo,;105-8512, Japan.;Japan Drug Information Institute in Pregnancy (J-TIS), National Center for Child;Health and Development, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan. |
|---|
